Perkins A C, Pimm M V
Eur J Nucl Med. 1985;11(8):295-9. doi: 10.1007/BF00252340.
The poor imaging characteristics of 131I have resulted in the use of alternative radionuclides for radiolabelling monoclonal antibodies. Clinical imaging studies have shown that, in addition to the more suitable energy of emission of 111In over 131I for gamma camera detection, the 111In-labelled antibody appears to clear from the bloodstream at a faster rate than that of 131I-labelled antibody, resulting in greater tumour-to-background image contrast. However, measurements of the activity in blood samples from patients demonstrate that both 131I- and 111In-labelled antibodies clear from the circulation at similar rates. This discrepancy is probably due to the different biological fates of the two radionuclides and warrants further scientific study.
131I成像特性不佳,促使人们使用其他放射性核素对单克隆抗体进行放射性标记。临床成像研究表明,除了111In发射的能量比131I更适合γ相机检测外,111In标记的抗体从血液中清除的速度似乎比131I标记的抗体更快,从而产生更高的肿瘤与背景图像对比度。然而,对患者血样活性的测量表明,131I和111In标记的抗体从循环系统中清除的速率相似。这种差异可能是由于两种放射性核素的生物学归宿不同,值得进一步开展科学研究。